Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT compared to a placebo in treating psychosis linked to Alzheimers Disease. This Phase 3 outpatient study lasts 38 weeks and aims to prevent relapse of psychosis symptoms in affected adults aged 55 to 90. The trial also looks at how long participants stay on treatment without relapse or stopping for any reason, along with monitoring safety and tolerability. Participants are randomly assigned to receive either KarXT capsules in varying doses or placebo capsules. The treatment is administered three times a day during the study period. This double-blind trial ensures neither participants nor researchers know which treatment is given. The study is conducted at multiple centers and includes a placebo control to compare outcomes. Throughout the 38 weeks, participants will attend regular visits for assessments including cognitive tests like the Mini-Mental State Examination, evaluations of psychosis severity, caregiver-reported measures, and safety monitoring such as laboratory tests, vital signs, and adverse event tracking. Researchers will measure the time to relapse and treatment discontinuation, along with side effects and other health indicators. The study is sponsored by Karuna Therapeutics, a Bristol Myers Squibb company.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT in adults aged 55 to 90 years with mild to severe Alzheimers Disease that includes moderate to severe psychosis symptoms. This Phase 3 study focuses on treating psychosis related to Alzheimers Disease using a randomized, double-blind, placebo-controlled design. Participants receive either KarXT or a placebo at specified doses on scheduled days. The study lasts up to 14 weeks, during which the impact of KarXT on hallucinations, delusions, and other neuropsychiatric symptoms is assessed. The research also monitors various safety measures and cognitive function throughout this period. During the study, participants undergo evaluations including neuropsychiatric inventories, clinical global impression scales, cognitive tests like the Mini-Mental State Examination and Alzheimers Disease Assessment Scale, as well as safety monitoring through laboratory tests, vital signs, ECGs, and assessments for adverse events. The primary outcome is the change in hallucinations and delusions score up to week 14, with ongoing safety and efficacy assessments throughout the treatment period.
Actively Recruiting
Researchers are conducting a Phase 3 global, multicenter, 52-week open-label extension study to assess the long-term safety and tolerability of KarXT in people with psychosis associated with Alzheimers Disease. This study includes participants who have completed prior related studies, allowing continued evaluation of this treatment over an extended period. Participants receive KarXT capsules in various doses ranging from 202 mg to 66.76.67 mg three times daily. This extension study follows completion of earlier trials and continues treatment for up to 52 weeks to monitor long-term effects and safety. During the study, participants are monitored for treatment-emergent adverse events from the initial dose through 14 days after the last dose, totaling up to 54 weeks. Researchers track serious adverse events and withdrawals due to adverse events. The involvement lasts approximately one year, focusing on safety and tolerability assessments.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of two drugs, EXV-802 and EXV-801, for treating agitation in people with Alzheimers Disease dementia. This Phase 23 study uses a double-blind, placebo-controlled design and includes approximately 300 participants diagnosed with Alzheimers-related agitation using standardized criteria and biomarker confirmation. The study is conducted at multiple centers across the US, Canada, and Europe. Participants are randomly assigned to one of three groups receiving EXV-802 capsules, EXV-801 capsules, or placebo capsules, each taken twice daily for six weeks. Screening occurs about four weeks before randomization to ensure eligibility, and the study follows a parallel model comparing these three arms. Treatment adherence and response are carefully monitored during this period. During the study, participants undergo assessments including the Cohen-Mansfield Agitation Inventory CMAI-IPA to measure agitation changes from baseline to week 6, and the Clinical Global Impression of Severity CGI-S scale to evaluate symptom severity. Caregivers must be involved and regularly in contact with participants. Safety and efficacy data are collected throughout, with the study expected to complete by early 2029.